On November 12, 2026 Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, reported an amendment to its existing agreement with RemeGen Co., Ltd (HKEX: 9995, SHA: 688331) to add RC298, a next-generation dual BAFF/APRIL inhibitor, to Vor Bio’s exclusive license for development and commercialization outside of Greater China.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

RC298 is an engineered TACI-Fc fusion protein designed to inhibit both BAFF (B cell activating factor) and APRIL (a proliferation-inducing ligand), two key regulators of pathogenic B cell and plasma cell biology. RC298 was engineered to optimize functional potency, pharmacokinetics, and developability with a structural design intended to enable sustained dual pathway inhibition and extended dosing intervals. In preclinical studies, RC298 demonstrated potent inhibition of BAFF and APRIL compared to leading BAFF/APRIL inhibitors, as well as significantly prolonged systemic exposure, supporting its potential for a differentiated, best-in-class efficacy and dosing profile.

Building on telitacicept as the clinical foundation of Vor Bio’s BAFF/APRIL franchise with three ongoing registrational trials advancing across the myasthenia gravis spectrum and Sjögren’s disease, RC298’s differentiated long-acting profile has the potential to expand the franchise into additional autoimmune diseases and treatment settings, extending the therapeutic reach of dual BAFF/APRIL inhibition.

RC298 is currently in IND-enabling development, with an IND submission in China anticipated in the first half of 2027. RemeGen will continue to lead the preclinical and Phase 1 clinical development of RC298 in China, with both companies contributing to development efforts. Following completion of the Phase 1 clinical trial, Vor Bio will assume responsibility for subsequent clinical development, regulatory activities, and commercialization of RC298 outside of greater China.

"Over the past year, our successful execution has established Vor as a leader in the BAFF/APRIL field and RC298 meaningfully strengthens that position," said Jean-Paul Kress, M.D., Chairman and Chief Executive Officer of Vor Bio. "Our conviction in building this franchise is reinforced by what FcRn therapies have already demonstrated across multiple large autoimmune diseases. We believe BAFF/APRIL can build on that precedent by acting both upstream on B cells and downstream on plasma cells, with the potential for deeper, broader, and more durable disease control."

Dr. Kress continued, "Telitacicept remains our clinical foundation and near-term priority as we execute on our global Phase 3 programs in myasthenia gravis and Sjögren’s disease. RC298 is the next step in our broader campaign to create opportunities with a long-acting, next generation molecule across new diseases and treatment settings. We are building on a biology we know deeply, alongside a partner with extraordinary clinical and commercial experience in the pathway. With multiple differentiated ways to target BAFF and APRIL, we believe Vor is best positioned to build the leading franchise in this category and deploy each molecule where its profile can create the greatest advantage for patients."

"Telitacicept is the world’s first approved innovative therapy to target both BAFF and APRIL for the treatment of a range of B cell-mediated autoimmune diseases. It has been approved in China for five indications, and its global multicenter clinical trials are progressing well. The clinical evidence to date has demonstrated the potential benefits of dual BAFF/APRIL inhibition. RC298, our next generation, long-acting dual BAFF/APRIL inhibitor, has shown best-in-class potential," said Dr. Jianmin Fang, Chief Executive Officer of RemeGen. "This transaction will broaden both companies’ global autoimmune disease portfolios and accelerate the international development of RemeGen’s innovative pipeline. With RC298, we aim to bring an innovative treatment option to patients with autoimmune diseases worldwide while strengthening RemeGen’s brand and expanding its global presence."

Transaction Terms

Under the terms of the agreement, Vor Bio will provide RemeGen with approximately $56 million in aggregate upfront consideration, consisting of a $10 million upfront cash payment and pre-funded warrants to purchase 2.3 million shares of Vor Bio common stock with an exercise price of $0.0001 per share (representing an approximate value of $46 million based on Vor Bio’s closing share price on November 11). RemeGen will be eligible to receive up to an additional $300 million in development milestone payments, including $20 million payable upon the achievement of initial clinical development and technology transfer milestones. The existing collaboration’s sales milestone and royalty framework will continue to apply on an aggregated basis across all licensed products.

About Telitacicept

Telitacicept is a novel recombinant fusion protein designed to treat autoimmune diseases through dual inhibition of BAFF (also known as BlyS) and APRIL – two cytokines essential to B cell development and plasma cell survival. By inhibiting both pathways, telitacicept has the potential to reduce autoreactive B cells and autoantibody production, targeting key drivers of autoimmune pathology.

Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), generalized myasthenia gravis (gMG), IgA nephropathy (IgAN), and Sjögren’s disease (SjD).

Vor Bio is advancing global development programs across major autoimmune indications, including a global Phase 3 trial in gMG and SjD, to support potential regulatory approvals in the United States, Europe, and Japan.

(Press release, Vor BioPharma, NOV 12, 2026, View Source [SID1234674690])